Transplantable Liver Organoids Made from Only Three Ingredients  by Willenbring, Holger & Soto-Gutierrez, Alejandro
Cell Stem Cell
PreviewsTransplantable Liver Organoids Made
from Only Three IngredientsHolger Willenbring1,* and Alejandro Soto-Gutierrez2,*
1Department of Surgery, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and Liver Center,
University of California, San Francisco, San Francisco, CA 94143, USA
2Department of Pathology and Department of Surgery
Children’s Hospital of Pittsburgh, McGowan Institute for Regenerative Medicine, and Thomas E. Starzl Transplantation Institute,
University of Pittsburgh, Pittsburgh, PA 15231, USA
*Correspondence: willenbringh@stemcell.ucsf.edu (H.W.), sotogutierreza@upmc.edu (A.S.-G.)
http://dx.doi.org/10.1016/j.stem.2013.07.014
Liver cell therapies using induced pluripotent stem cells (iPSCs) are in development. A recent paper inNature
by Takebe et al. expands the range of liver diseases that could be treated with iPSC-derived hepatocytes
by combining them with endothelial and stromal cells to generate organoids that survive and function
extrahepatically.Possibly the greatest potential of human
induced pluripotent stem cells (iPSCs)
lies in autologous cell therapies requiring
no or little immune suppression. The liver
is a particularly promising target for cell
therapy because of its inherent ability to
integrate newly formed cells, including
hepatocytes, which provide most of the
liver’s functions. While current protocols
for generating hepatocytes from iPSCs
(iPSC-Heps) yield incompletely differenti-
ated cells, there is steady progress
toward obtaining iPSC-Heps that are
equivalent to primary human hepatocytes
in both function and ability to proliferate.
However, clinical experience with primary
human hepatocyte transplantation sug-
gests that using fully functional cells and
protecting them from immune rejection
is not a guarantee for successful liver
cell therapy (Puppi et al., 2012). To be
therapeutically effective, transplanted
cells also need to efficiently engraft and
survive long term—factors that are
impacted by the liver microenvironment
and thus the underlying disease. Unfortu-
nately, most liver diseases are associated
with fibrosis, which in its most advanced
form, cirrhosis, impairs engraftment,
survival, and function of transplanted
hepatocytes (Liu et al., 2012). Therefore,
extrahepatic transplantation sites such
as lymph nodes are currently being
pursued to realize the full potential of liver
cell therapy (Hoppo et al., 2011).
A promising alternative approach has
now been reported by Takebe et al.
(2013). Instead of introducing iPSC-Heps
into a hostile or foreignmicroenvironment,
the authors delivered the cells to extrahe-patic sites as self-contained organoids
mimicking embryonic liver (Figure 1).
They started by generating hepatic endo-
derm cells from human iPSCs (iPSC-
HECs) using standard protocols. Because
stromal and endothelial cells provide
essential cues for liver development
(Zaret and Grompe, 2008), the authors
reasoned that adding human umbilical
vein endothelial cells (HUVECs) and
human mesenchymal stem cells (MSCs)
to the iPSC-HECs could assist in proper
differentiation. Surprisingly, within a day,
the authors observed that the three cell
types began to self-assemble into 3D
organoids in which the MSCs provided
structural support and the HUVECs orga-
nized into a loose web. Thismicroenviron-
ment promoted hepatocyte differentiation
of the iPSC-HECs, eventually producing
iPSC-Heps that were still immature, but
expressed certain liver functions at higher
levels than iPSC-Heps generated in 2D
cultures.
The organoids could be detached from
the culture matrix, which facilitated
transplanting them as intact structures.
Initially, Takebe et al. placed single orga-
noids on the brains of immune-deficient
mice and monitored them through cranial
windows. Only 2 days after transplanta-
tion, the organoids exhibited HUVEC-
derived blood vessels that were con-
nected to the host circulation and rapidly
formed a complex vascular network. This
finding of spontaneous organization of
HUVECs into functional blood vessels
in vivo is reminiscent of previous studies
(Koike et al., 2004), which also estab-
lished the importance of MSCs as aCell Stem Cell 1source of pericytes promoting vessel
stability.
Analysis of the organoids 2 months
after transplantation revealed that they
were viable and had undergone further
maturation. Histologically, organoids
resembled adult liver in that iPSC-Heps
had assumed a cuboidal shape, were
organized in cords, and had formed bile
canaliculi with adjacent iPSC-Heps. How-
ever, because there were no bile ducts,
bile produced by the iPSC-Heps was
likely released into the circulation, which
may be tolerated if the recipient’s native
liver retains excretory function (Hoppo
et al., 2011). Integrated organoids allowed
analysis of human-specific drug meta-
bolism, suggesting further differentiation
of iPSC-Heps in vivo. However, iPSC-
Heps were not fully differentiated, as
evidenced by lower albumin secretion
and lower expression of hepatocyte-
specific CYP450 enzymes than previously
reported for primary human hepatocytes
(Azuma et al., 2007). The authors attrib-
uted this deficiency to delayed differentia-
tion of human cells in mice, a possibility
that could be addressed by following
transplanted organoids for more time.
Alternatively, the iPSC line or the differen-
tiation protocol used may not allow
completion of hepatocyte differentiation
in vivo, or iPSC-Heps may require ex-
posure to the specialized stromal and
endothelial cells or the venous-arterial
blood mix found in the normal liver for
full differentiation.
Takebe et al. also established trans-
plantation of numerous organoids into
extrahepatic sites, namely the space3, August 1, 2013 ª2013 Elsevier Inc. 139
Figure 1. Transplantation of Liver Organoids into Extrahepatic Sites such as the Mesentery
as a Potential Therapy for Liver Cirrhosis
Arteries are shown in red, veins in blue, and biliary structures in green. Only the veins of the mesentery are
shown.
Cell Stem Cell
Previewsunder the kidney capsule and, with an eye
toward clinical translation, the mesentery.
They showed that transplanting 12 orga-
noids (corresponding to 1% of a
mouse’s hepatocytemass) on themesen-
tery was effective in protecting mice from
subacute liver failure. Because the human
liver contains 1,000 times more hepato-
cytes than the mouse liver, translating
these promising results into a therapy for
patients with liver disease will depend on
whether the approach can be significantly
scaled up. As first evidence for the feasi-
bility of scaling, Takebe et al. found spon-
taneous proliferation of iPSC-Heps in
transplanted organoids, resulting in 20-
fold expansion. iPSC-Hep proliferation
could be further increased by 2/3 partial
hepatectomy, which suggests that hepa-
tocyte growth factors could be used for
noninvasive posttransplant expansion.
As an alternative to transplanting a large
number of organoids and expanding
them in vivo, it may be possible to
assemble numerous organoids in a decel-140 Cell Stem Cell 13, August 1, 2013 ª2013lularized liver matrix in vitro to generate a
single transplantable structure that could
be connected to both venous and arterial
circulation (Uygun et al., 2010). Recellula-
rizing natural liver scaffolds has proven to
be difficult, and using organoids as self-
connecting building blocks may facilitate
the formation of a functional vascular
network, particularly if flow is provided
by perfusing the scaffold through the por-
tal vein.
Finally, although not investigated in the
study by Takebe et al., generating entirely
autologous organoids requiring no or little
immune suppression appears feasible. To
do so may simply require following estab-
lished protocols for the directed differenti-
ation of human embryonic stem cells into
endothelial cells and MSCs (Gruenloh
et al., 2011; Wang et al., 2007).
The study by Takebe et al. has implica-
tions beyond liver cell therapy. The ease
with which liver organoids could be
generated and engrafted serves to remind
us that cells normally work in concert withElsevier Inc.other cells, and that they carry information
on how to come together as a viable
tissue, properties to be considered and
harnessed for regenerative medicine.ACKNOWLEDGMENTS
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